An interventional study of AI-Enabled Stratified Management System and Usual post-discharge care in Secondary Prevention of Coronary Heart Disease, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.
Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases — 12 open to participants now, 13 under way, none of them phase 3. Coronary Disease · China National Center for Cardiovascular Diseases.
Among the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases, this one is the 9th largest by planned enrollment of the 13 interventional ones that give a count, is one of 6 that started in 2025, is one of 7 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 21st registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →12 of the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–45
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–45
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 160 across 780 interventional studies indexed under Coronary Disease.
Median enrollment 240 across the 13 interventional studies, 5,000 across the 12 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.
4 of the studies in Coronary Disease by China National Center for Cardiovascular Diseases that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07259278China National Center for Cardiovascular DiseasesIntelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients | 2026-11-30 |
| NCT07230847China National Center for Cardiovascular DiseasesA Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography | 2026-12-31 |
| NCT07766551China National Center for Cardiovascular DiseasesConstruction and Validation of a Coronary Artery Disease-Specific Large Language Model and Its Evaluation Framework (CorAI) | 2027-01-01 |
| NCT07004452China National Center for Cardiovascular DiseasesMulti-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Coronary Disease by China National Center for Cardiovascular Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to find out if an artificial intelligence (AI)-enabled stratified management platform can help adults with coronary heart disease (CHD) better perform exercise rehabilitation and manage their health after being discharged from the hospital. The main questions it aims to answer are:
Researchers will compare the AI Management Group (using the platform and a sports wristband) to the Routine Management Group (receiving usual care without the platform) to see if the AI group shows more significant improvements in fitness and health metrics.
Participants will:
The study hopes to show that this intelligent management platform is an effective and safe tool to help people with CHD recover at home, stay active, and reduce future heart risks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the intervention group will receive comprehensive post-hospital rehabilitation management through an AI-based stratified management platform, utilizing a smartphone app and wearable device to track health data, deliver reminders and immediate safety alerts.
Combination Product: AI-Enabled Stratified Management System · Combination Product: Usual post-discharge care
Participants in the control group will receive usual discharge protocol and personalized exercise prescription and goals from a specialist.
Combination Product: Usual post-discharge care
Following discharge, participants in the AI-stratified management group will use an intelligent platform (smartphone app + wearable divice) for home-based exercise rehabilitation and comprehensive post-discharge care. Key features include: 1) Safety Monitoring \& Alerts: Real-time tracking of heart rate and other parameters via wristband triggers immediate safety warnings during exercise; 2) Holistic Risk Management: Integrated support for lifestyle modification, medication adherence, and control of cardiovascular risk factors; 3) Structured Engagement: Multi-channel reminders (messages, alarms, voice calls) for medications, exercise, and follow-ups to sustain adherence.
Usual discharge protocol comprising verbal and printed discharge instructions addressing medication schedules, follow-up timelines, and lifestyle optimization strategies as well as a personalized exercise prescription.
Peak oxygen consumption (VO2peak)
Peak oxygen consumption (VO2peak, mL∙kg-¹min-¹)
Time frame: From enrollment to the end of treatment at 3 months.
Change in 6-minute walk distance
6-minute walk distance (m)
Time frame: From enrollment to the end of treatment at 3 months
Change in physical activity level (MET-min/week)
Physical activity level (MET-min/week), estimated using the International Physical Activity Questionnaire-Short Form (IPAQ-SF). It consists of 7 questions with a recall period defined as 'last week'. The questions of the scale ask whether the participant walks for at least 10 minutes on any given day or does moderate or vigorous activities, and how much time/day the individual spends on each of these activities or sit.
Time frame: From enrollment to the end of treatment at 3 months
Change in average daily step count
Average daily step count (steps per day)
Time frame: From enrollment to the end of treatment at 3 months
Exercise adherence
In the self-reported exercise diary, the participant will note the number of exercises done at home. The percentage adherence to the prescribed exercise regimen was calculated by dividing the number of exercises performed by the number of exercises prescribed and multiplying by 100.
Time frame: From enrollment to the end of treatment at 3 months.
Composite endpoints
A composite endpoint including all-cause mortality, cardiac arrest, non-fatal myocardial infarction, and symptom-driven unplanned rehospitalization occurring during exercise. Safety endpoint during rehabilitation.
Time frame: From enrollment to the end of treatment at 3 months
Systolic blood pressure (mmHg)
Systolic blood pressure. Unit of Measure: mmHg.
Time frame: From enrollment to the end of treatment at 3 months
Diastolic blood pressure (mmHg)
Diastolic blood pressure. Unit of Measure: mmHg.
Time frame: From enrollment to the end of treatment at 3 months
Glycated hemoglobin (HbA1c, %)
Glycated hemoglobin. Unit of Measure: %.
Time frame: From enrollment to the end of treatment at 3 months
Low-density lipoprotein cholesterol (LDL-C, mmol/L)
Unit of Measure: mmol/L
Time frame: From enrollment to the end of treatment at 3 months
Body mass index (BMI, kg/m^2)
Time frame: From enrollment to the end of treatment at 3 months
Unplanned rehospitalization due to cardiovascular causes
Time frame: From enrollment to the end of treatment at 3 months
Major Adverse Cardiovascular Events (MACE)
Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
Time frame: From enrollment to the end of treatment at 3 months
Anxiety level by Generalized Anxiety Disorder-7 scale score
Anxiety level, assessed using the Generalized Anxiety Disorder-7 (GAD-7) questionnaire. Patients will be evaluated at the beginning and at the endpoint of the study with the self-administered GAD-7 scale. The GAD-7 scale score ranges from 0 to 21 points. A score between 5 and 9 points characterizes mild GAD. Between 10 and 14, moderate GAD and between 15 and 21, severe GAD.
Time frame: From enrollment to the end of treatment at 3 months
Depression level by Patient Health Questionnaire-9 (PHQ-9)
Depression level, assessed using the Patient Health Questionnaire-9 (PHQ-9). The GAD-7 scale score ranges from 0 to 27 points. A score between 5 and 9 points characterizes mild depression. Between 10 and 14, moderate depression; between 15 and 19, moderate-severe depression; and between 20 and 27, severe depression.
Time frame: From enrollment to the end of treatment at 3 months
Sleep quality, assessed using the Pittsburgh Sleep Quality Index (PSQI)
Sleep quality, assessed using the Pittsburgh Sleep Quality Index (PSQI). The total score ranges from 0 to 21 with a higher score indicating poor quality of sleep (worse). The higher the score, the worse the sleep quality. A cut-off score of \>5 indicates poor sleep quality.
Time frame: From enrollment to the end of treatment at 3 months
Quality of life by the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire
Quality of life, assessed using the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire. This questionnaire asks 5 multiple-choice questions about mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. EQ-5D-5L index scores range from 0 to 100, where 100 is the best possible health state.
Time frame: From enrollment to the end of treatment at 3 months
Plan to share: Yes — Individual participant data (IPD) that underlie the results reported in publications will be shared, including all collected de-identified IPD.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will be available beginning 6 months after publication of the primary results and will remain available for at least 5 years thereafter.
Access criteria: De-identified IPD and supporting documents will be made available upon reasonable request to the Principal Investigator (PI). Requests must include a methodologically sound proposal and intended use. Access will be granted at the discretion of the PI after review of the request.
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Nov 2026, 11 months later.
Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 11 months is below that.
Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →